Novartis (NVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novartis (NVS) reachead $102.22 at the closing of the latest trading day, reflecting a -0.9% change compared to its last close.

Britain's health regulator said on Wednesday it had revoked a conditional marketing authorisation for Novartis' sickle cell disease drug, Adakveo.

Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has unveiled changes to a seven-year agreement with Novartis Pharmaceuticals for the distribution of its eye treatment. Xiidra, a treatment for dry eye, wil...

Novartis CEO Vasant Narasimhan joins 'Money Movers' to discuss the company's quarterly earnings results, the company's warning about losing exclusivity in some products, and if the sector will be a...

Novartis (NVS) announced fourth-quarter results and guidance Wednesday that fell short of analyst's expectations, and the company also ended a study on an experimental blood cancer treatment. Ameri...

Novartis AG (NVS) Q4 2023 Earnings Call Transcript

Novartis' (NVS) earnings and sales miss estimates in the fourth quarter. The outlook for 2024 does not look promising as well.

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall S...

Vas Narasimhan, CEO of Novartis, discusses fourth-quarter results, weight loss drugs and the company's U.S. targets.

Switzerland's Novartis on Wednesday updated its mid-term guidance, saying it expected sales to grow 5% per year until 2028, when adjusting for currency swings.

Besides Wall Street's top -and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the...

Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.

One of the top topics at the World Economic Forum is generative AI, with endless discussions on how it can impact a broad range of sectors and businesses. Pharmaceutical drug development is one of ...